Advaxis, Inc. Announces Amendment of Proxy Statement Supplement Further Reduction in Share Capital Proposal
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has filed a Form DEFR14A with the U.S. Securities and Exchange Commission to amend its Proxy Statement Supplement dated May 22, 2013.
Help employers find you! Check out all the jobs and post your resume.
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has filed a Form DEFR14A with the U.S. Securities and Exchange Commission to amend its Proxy Statement Supplement dated May 22, 2013.
Help employers find you! Check out all the jobs and post your resume.